TABLE 1.

Demographics and Clinical Characteristics of Patients Included in the Study

Patient ID	1	2	3	4	5	Median (range)
Clinical characteristics
Age (years)	44	62	43	53	31	44 (31:62)
Gender	F	M	M	M	M
Ethnicity	White	White	White	White	White
Overall survival (months)	25	9	7	10	4	9 (4:25)
Status	Alive	Alive	Alive	Dead	Dead
Stage
AJCC classification	M1c	M1a	M1c	M1c	M1c
Sites of Metastatic Disease	Bone, lung, nodal, soft tissue	Lymph nodes	Soft tissue, liver lesion	Lung, stomach, soft tissue	Pleura
LDH UI/L	141	169	233	442	365	233 (141:442)
Treatment
Drug	Pembrolizumab	Pembrolizumab	Pembrolizumab	Pembrolizumab	Pembrolizumab
Response 6 weeks (FLT-PET, PERCIST)	PR	PR	SD	SD	PD
Response – 12 weeks (CT, RECIST)	CR	PR	PR	SD	PD
Baseline FLT-PET
Uptake
SUV max	12.1	5.9	5,5	8.4	5.2	5.9 (5.2:12.1)
SUV peak	9.7	4.8	3,7	7.4	3.9	4.8 (3.7:9.7)
SUV mean	3.7	3.8	3,1	5.2	2.8	3.7 (2.8:5.2)
SUV SD	1	0.7	0,8	1.1	0.5	0.8 (0.5:1.1)
Tumor Burden
TLP	226	106	14	349	353	225 (14:353)
PTV	60	28	5	67	128	60 (5:128)
Healthy Hematopoietic Tissue Metabolism
SLR	34%	41%	33%	60%	61%	41% (33%:61%)
BLR	137%	125%	129%	98%	79%	125% (79%:137%)
6-week (Delta) FLT-PET
Uptake
Delta-SUV max	−75%	−40%	−22%	−14%	233%	−22% (−75%:233%)
Delta-SUV peak	−74%	−53%	−15%	−15%	295%	−15% (−74%:295%)
Delta-SUV mean	−54%	−52%	−17%	−17%	203%	−17% (−54%:203%)
Delta-SD	−89%	−63%	−17%	−31%	5%	−31% (−89%:5%)
Tumor Burden
Delta- TLP	−91%	−85%	−32%	63%	8773%	−32% (−91%:8773%)
Delta- PTV	−79%	−69%	−18%	96%	2830%	−18% (−79%:2830%)
Healthy Hematopoietic Tissue Metabolism
Delta-SLR	47%	0%	−9%	−27%	4%	0% (−27%:47%)
Delta-BLR	−4%	12%	21%	38%	9%	12% (−4%:38%)